Quest Diagnostics (DGX) Stock Price, News & Analysis

Quest Diagnostics Incorporated (NYSE: DGX) is a medical laboratories company in the health care and social assistance sector that focuses on diagnostic testing and diagnostic information services. According to the company, it works across the healthcare ecosystem to provide diagnostic insights from laboratory testing that help people, physicians and organizations take actions aimed at improving health outcomes. Quest Diagnostics is described as a leading independent provider of diagnostic testing, information and services in the United States.

The company indicates that it derives diagnostic insights from one of the world's largest databases of de-identifiable clinical laboratory results. By analyzing this data, Quest Diagnostics states that it can reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. These insights are intended to support clinical decisions and population health strategies across many care settings.

Quest Diagnostics reports that it annually serves one in three adult Americans and half of the physicians and hospitals in the United States. Its workforce numbers more than 55,000 employees, who the company describes as focused on ensuring that diagnostic information, when interpreted in the right context, can inspire actions that transform lives and contribute to a healthier world. This scale of testing and data generation underpins the firm’s position in the medical laboratories industry.

The firm’s core operations center on diagnostic testing. Quest Diagnostics generates the vast majority of its revenue from clinical testing, anatomic pathology, esoteric testing and substance abuse testing. Specimens for these services are collected through a national network of patient service centers, as well as doctors’ offices and hospitals. The company also operates a diagnostic solutions segment that offers clinical trials testing, risk-assessment services and information technology solutions.

Business model and diagnostic services

Clinical laboratory testing is at the heart of Quest Diagnostics’ business model. The company’s testing services encompass a broad menu of diagnostic tests. Through its national network of patient service centers and relationships with physicians and hospitals, Quest Diagnostics collects specimens that are processed in its laboratories and translated into diagnostic reports. These reports provide physicians and other healthcare professionals with information used in screening, diagnosis, treatment selection and monitoring of many conditions.

Quest Diagnostics also highlights its role in providing diagnostic information services. These services extend beyond the raw test result and include the interpretation and delivery of diagnostic insights. The company emphasizes that its large database of de-identifiable clinical lab results allows it to derive patterns and insights that can inform clinical practice and healthcare management. This focus on information and insight differentiates basic testing from broader diagnostic decision support.

In addition to routine clinical testing, Quest Diagnostics performs anatomic pathology, esoteric testing and substance abuse testing. Anatomic pathology typically involves the examination of tissues, while esoteric testing often refers to highly specialized or complex tests. Substance abuse testing is used in clinical care and other settings where information about drug use is relevant. Together, these testing categories form the primary sources of revenue for the company.

The company’s smaller diagnostic solutions segment provides clinical trials testing, risk-assessment services and information technology solutions. Clinical trials testing supports biopharmaceutical and research organizations that require laboratory data to evaluate investigational therapies. Risk-assessment services and information technology solutions are designed to support decision-making by payers, providers and other stakeholders who need structured diagnostic data and analytics.

Role in the healthcare ecosystem

Quest Diagnostics describes itself as working across the healthcare ecosystem to create a healthier world, one life at a time. By providing diagnostic insights, the company aims to empower patients, physicians and organizations to take action to improve health outcomes. The firm states that its diagnostic insights can reveal new ways to identify and treat disease, encourage healthier behaviors and improve the management of healthcare resources.

The company’s scale is reflected in its claim that it serves one in three adult Americans each year and half of the physicians and hospitals in the United States. This reach positions Quest Diagnostics as a key participant in national healthcare delivery, particularly in the area of laboratory medicine. Its network of patient service centers and in-office phlebotomists, as referenced in collaboration announcements, supports specimen collection for a wide range of diagnostic tests.

Quest Diagnostics also participates in joint ventures and collaborations that extend its presence in regional markets and specialized testing areas. For example, Sonora Quest Laboratories is described as an Arizona-based joint venture between Banner Health and Quest Diagnostics that forms one of the nation’s largest integrated laboratory systems. Sonora Quest is characterized as a trusted leader in diagnostic and information services in Arizona, performing more than 100 million diagnostic tests per year and offering a comprehensive test menu that includes routine, molecular, prescription drug monitoring, genetic/genomic, women’s health and pathology testing services.

Another example is the laboratory services joint venture with Corewell Health in Michigan, named Diagnostic Lab of Michigan, LLC. In this arrangement, equity ownership is shared between Quest Diagnostics and Corewell Health. The joint venture is intended to expand access to laboratory services in Michigan. In addition, Quest’s Collaborative Lab Solutions (Co-Lab) hospital lab management services have begun to take effect across Corewell Health’s hospitals, covering areas such as supply chain, lab management, patient blood and anemia management, lab analytics and stewardship, and reference testing.

Innovation and specialized diagnostics

Quest Diagnostics is active in specialized areas of diagnostics, including oncology and neurology. Through its wholly owned subsidiary Haystack Oncology, the company is involved in the development and commercialization of Haystack MRD, a tumor-informed, next-generation minimal residual disease (MRD) test that detects ultralow levels of circulating tumor DNA (ctDNA). Haystack MRD is described as a highly sensitive test used to uncover residual or recurrent disease in solid tumors.

Haystack Oncology works with biopharmaceutical companies to support clinical development programs and companion diagnostics. Haystack MRD was developed and validated in a CLIA-certified laboratory and is available for commercial use as a lab-developed test by Quest Diagnostics. It is also available for clinical trials as an investigational device in laboratories located in Baltimore, Maryland; Hamburg, Germany; and Helsinki, Finland. Data featuring Haystack MRD have been presented at scientific meetings, such as the ASCO Gastrointestinal Cancers Symposium, including studies evaluating ctDNA in colorectal cancer and rectal cancer.

Quest Diagnostics is also collaborating in research to evaluate Haystack MRD as a guide for post-surgical treatment in non-small cell lung cancer. In partnership with Rutgers Cancer Institute and RWJBarnabas Health, a clinical study is assessing whether the presence of residual tumor DNA after surgery, measured by Haystack MRD, can help guide the use of radiation and systemic therapies in patients with stage II/III non-small cell lung cancer.

In neurology, Quest Diagnostics has entered into a strategic collaboration with Octave Bioscience to expand patient access to the Octave Multiple Sclerosis Disease Activity (MSDA) Test. This collaboration allows providers who order the test from Octave to refer patients to Quest’s patient service centers and in-office phlebotomists for specimen collection. The Octave MSDA Test is described as a clinically and analytically validated multi-analyte blood test that reports an MS disease activity score and is intended to provide clinicians with objective data to support treatment decisions in multiple sclerosis.

Joint ventures and regional laboratory systems

Quest Diagnostics participates in joint ventures that combine its diagnostic capabilities with regional health systems. Sonora Quest Laboratories, a subsidiary of Laboratory Sciences of Arizona, is an Arizona-based joint venture between Banner Health and Quest Diagnostics. Sonora Quest is described as one of the nation’s largest integrated laboratory systems, with approximately 3,900 employees and more than 100 million diagnostic tests performed per year. It operates over 70 patient service centers across Arizona and offers a broad test menu that includes routine and specialized testing.

Sonora Quest is accredited by the College of American Pathologists, which is referred to as a gold standard in laboratory accreditation. The joint venture has also developed a direct-access testing platform, My Lab ReQuest, which allows patients to order certain laboratory tests without a provider’s order, and has undertaken initiatives such as Operation Catapult to expand COVID-19 diagnostic testing capacity in Arizona.

In Michigan, Quest Diagnostics and Corewell Health have formed Diagnostic Lab of Michigan, LLC, a laboratory services joint venture with shared equity ownership. Quest and Corewell Health’s existing laboratories will provide services to the joint venture while a new laboratory facility is developed. Quest’s Collaborative Lab Solutions hospital lab management services are being deployed across Corewell Health’s hospitals, with initiatives that include supply chain and lab management, patient blood and anemia management, lab analytics and stewardship, and reference testing.

Capital markets presence and investor communications

Quest Diagnostics’ common stock trades on the New York Stock Exchange under the symbol DGX. The company engages with investors through earnings releases, conference calls and presentations at healthcare conferences. For example, Quest Diagnostics has announced dates for reporting quarterly and full-year financial results and has held conference calls to discuss its performance and market developments. The company has also participated in events such as the J.P. Morgan Healthcare Conference and Citi’s Global Healthcare Conference, where its leadership discusses strategy, performance and market trends.

The company files current reports on Form 8-K with the U.S. Securities and Exchange Commission (SEC) to disclose material events, including quarterly financial results and investor presentations. These filings may include or reference press releases and presentation materials that provide additional information on the company’s operations, financial condition and strategic priorities.

Corporate purpose and positioning

Across its public communications, Quest Diagnostics emphasizes a purpose-driven approach centered on creating a healthier world, one life at a time. The company positions its diagnostic testing and information services as tools that can empower individuals and organizations to improve health outcomes. By combining large-scale laboratory operations, extensive data assets and collaborations with health systems and specialized diagnostic companies, Quest Diagnostics plays a significant role in the medical laboratories industry and in the broader healthcare ecosystem.